Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Sperrin M, Diaz-Ordaz K, Pajouheshnia R. Invited commentary: treatment drop-in-making the case for causal prediction. Am J Epidemiol. 2021 Oct 1;190(10):2015-8. doi: 10.1093/aje/kwab030.
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Sturmer T, Webster-Clark M, Lund JL, Wyss R, Ellis AR, Lunt M, Rothman KJ, Glynn RJ. Propensity score weighting and trimming strategies to reduce variance and bias of treatment effect estimates: a simulation study. Am J Epidemiol. 2021 Aug 1;190(8):1659-70. doi: 10.1093/aje/kwab041
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Rothman KJ. Rothman responds to “Surprise!” - Commentary. Am J Epidemiol. 2021 Feb 1;190(2):194-5. doi: 10.1093/aje/kwaa137
Harlow AF, Hatch EE, Wesselink AK, Rothman KJ, Wise LA. Electronic cigarettes and fecundability: results from a prospective preconception cohort study. Am J Epidemiol. 2021 Feb 1;190(3):353-61. doi: 10.1093/aje/kwaa067